Bulletin
Investor Alert

New York Markets Close in:

Market Snapshot Winners and Losers

International Flavors & Fragrances Inc.

NYS: IFF

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
International Flavors & Fragrances Inc.

Market open

 --Real time quotes

Jun 8, 2023, 10:23 a.m.

IFF
/zigman2/quotes/206698429/composite

$

80.92

Change

-0.28 -0.34%

Volume

Volume 219,314

Real time quotes

/zigman2/quotes/206698429/composite

Previous close

$ 81.20

$ 80.92

Change

-0.28 -0.34%

Day low

Day high

$80.72

$81.92

Open

52 week low

52 week high

$76.11

$133.23

Open

Company Description

International Flavors & Fragrances, Inc. engages in the manufacture and supply of flavors and fragrances used in the food, beverage, personal care, and household products industries. It operates through the following segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. The Nourish se...

International Flavors & Fragrances, Inc. engages in the manufacture and supply of flavors and fragrances used in the food, beverage, personal care, and household products industries. It operates through the following segments: Nourish, Health & Biosciences, Scent and Pharma Solutions. The Nourish segment consists of legacy Taste segment combined with N&B's Food & Beverage division and the food protection business of N&B's Health & Biosciences division. The Health & Biosciences business consists of a biotechnology-driven portfolio of enzymes, food cultures, probiotics and specialty ingredients for food, home and personal care, and health and wellness applications. The Scent business creates fragrance compounds, fragrance ingredients and cosmetic ingredients that are integral elements in the world’s finest perfumes and best-known household and personal care products. The Pharma Solutions business produces a vast portfolio including cellulosics and seaweed-based pharma excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling. The company was founded in 1833 and is headquartered in New York, NY.

Valuation

Price to Sales Ratio

2.15

Price to Book Ratio

1.51

Price to Cash Flow Ratio

67.34

Enterprise Value to EBITDA

13.52

Enterprise Value to Sales

2.57

Total Debt to Enterprise Value

0.31

Efficiency

Revenue/Employee

505,691.00

Income Per Employee

-75,935.00

Receivables Turnover

5.69

Total Asset Turnover

0.33

Liquidity

Current Ratio

1.99

Quick Ratio

1.15

Cash Ratio

0.13

Profitability

Gross Margin

27.52

Operating Margin

9.22

Pretax Margin

-13.06

Net Margin

-15.02

Return on Assets

-4.98

Return on Equity

-9.64

Return on Total Capital

3.65

Return on Invested Capital

-6.11

Capital Structure

Total Debt to Total Equity

65.81

Total Debt to Total Capital

39.69

Total Debt to Total Assets

32.87

Long-Term Debt to Equity

61.92

Long-Term Debt to Total Capital

37.34

Officers and Executives

Name Age Officer Since Title
Dr. Roger Walton Ferguson 69 2010 Independent Director
Mr. Franklin K. Clyburn 56 2022 Chief Executive Officer & Director
Mr. Glenn Robert Richter 59 2021 Chief Financial Officer & Executive Vice President
Mr. Vic Verma 53 2016 Chief Information Officer & Senior Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/04/2023 Christina A. Gold
Director 		1,245   Derivative/Non-derivative trans. at $0 per share. 0
05/04/2023 Barry A. Bruno
Director 		1,245   Derivative/Non-derivative trans. at $0 per share. 0
05/04/2023 Mark J. Costa
Director 		468   Derivative/Non-derivative trans. at $0 per share. 0
05/04/2023 Dawn C. Willoughby
Director 		434   Derivative/Non-derivative trans. at $0 per share. 0
05/04/2023 Gaoxiang Hu
Director 		434   Derivative/Non-derivative trans. at $0 per share. 0
05/04/2023 Kevin O'Byrne
Director 		262   Derivative/Non-derivative trans. at $0 per share. 0
04/06/2023 Christophe de Villeplee
President, Scent 		913   Derivative/Non-derivative trans. at $0 per share. 0
04/06/2023 Christophe de Villeplee
President, Scent 		1,188   Derivative/Non-derivative trans. at $0 per share. 0
04/06/2023 Gregory Yep
EVP, Chief Scientific Officer 		2,665   Derivative/Non-derivative trans. at $0 per share. 0
04/06/2023 Gregory Yep
EVP, Chief Scientific Officer 		733   Derivative/Non-derivative trans. at $91.45 per share. 67,032
04/01/2023 Simon W. Herriott
President Health & Biosciences 		461   Derivative/Non-derivative trans. at $90.6 per share. 41,766
04/01/2023 Simon W. Herriott
President Health & Biosciences 		1,489   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2023 Franklin K. Clyburn
Chief Executive Officer 		477   Derivative/Non-derivative trans. at $91.64 per share. 43,712
03/01/2023 Franklin K. Clyburn
Chief Executive Officer 		1,323   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2023 Simon W. Herriott
President Health & Biosciences 		177   Derivative/Non-derivative trans. at $96.13 per share. 17,015
02/19/2023 Angela Strzelecki
President, Pharma Solutions 		176   Derivative/Non-derivative trans. at $96.13 per share. 16,918
02/19/2023 Jennifer A. Johnson
EVP, General Counsel 		293   Derivative/Non-derivative trans. at $96.13 per share. 28,166
02/19/2023 Simon W. Herriott
President Health & Biosciences 		617   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2023 Angela Strzelecki
President, Pharma Solutions 		584   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2023 Jennifer A. Johnson
EVP, General Counsel 		708   Derivative/Non-derivative trans. at $0 per share. 0
01/24/2023 Michael L. Ducker
Director 		2,210   Derivative/Non-derivative trans. at $0 per share. 0
01/03/2023 Francisco Fortanet
EVP, Operations 		2,229   Derivative/Non-derivative trans. at $103.11 per share. 229,832
01/03/2023 Angela Strzelecki
President, Pharma Solutions 		487   Derivative/Non-derivative trans. at $105.64 per share. 51,446
01/03/2023 Francisco Fortanet
EVP, Operations 		5,254   Derivative/Non-derivative trans. at $0 per share. 0
01/03/2023 Christophe de Villeplee
President, Scent 		784   Derivative/Non-derivative trans. at $0 per share. 0
01/03/2023 Angela Strzelecki
President, Pharma Solutions 		1,341   Derivative/Non-derivative trans. at $0 per share. 0
11/01/2022 Jennifer A. Johnson
EVP, General Counsel 		376   Derivative/Non-derivative trans. at $95.45 per share. 35,889
11/01/2022 Jennifer A. Johnson
EVP, General Counsel 		1,041   Derivative/Non-derivative trans. at $0 per share. 0
10/03/2022 Glenn Robert Richter
CFO 		11,812   Derivative/Non-derivative trans. at $0 per share. 0
08/11/2022 Francisco Fortanet
EVP, Operations 		10,000   Disposition at $125 per share. 1,250,000
/news/latest/company/us/iff

MarketWatch News on IFF

  21. Loading more headlines...
/news/nonmarketwatch/company/us/iff

Other News on IFF

  1. 10-Q: INTERNATIONAL FLAVORS & FRAGRANCES INC

    9:16 a.m. May 10, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. Bestinver's 4th-Quarter Letter

    5:47 p.m. March 9, 2023

    - GuruFocus.com

  4. Top 5 4th Quarter Trades of First Pacific Advisors

    7:00 p.m. Feb. 16, 2023

    - GuruFocus.com

  5. Daniel Loeb Buys AIG, Adds to Bath & Body Works Stake

    12:58 p.m. Feb. 16, 2023

    - GuruFocus.com

  6. Top 5 4th Quarter Trades of Daniel Loeb

    5:00 p.m. Feb. 14, 2023

    - GuruFocus.com

  8. Top 5 4th Quarter Trades of First Pacific Advisors

    1:00 p.m. Feb. 14, 2023

    - GuruFocus.com

  9. Top 5 4th Quarter Trades of WEIK CAPITAL MANAGEMENT

    5:00 p.m. Feb. 10, 2023

    - GuruFocus.com

  12. Top 5 4th Quarter Trades of FRONT BARNETT ASSOCIATES LLC

    7:00 p.m. Feb. 6, 2023

    - GuruFocus.com

  13. Robert Olstein Buys 3, Sells 2 in 4th Quarter

    1:00 p.m. Feb. 6, 2023

    - GuruFocus.com

  14. Top 5 4th Quarter Trades of Searle & Co.

    11:00 a.m. Feb. 6, 2023

    - GuruFocus.com

  16. Bestinfond's Top 4th-Quarter International Buys

    6:13 p.m. Feb. 1, 2023

    - GuruFocus.com

  17. Top 5 4th Quarter Trades of Sarasin & Partners LLP

    7:00 p.m. Jan. 30, 2023

    - GuruFocus.com

  19. Top 5 4th Quarter Trades of ZWJ INVESTMENT COUNSEL INC

    3:00 p.m. Jan. 24, 2023

    - GuruFocus.com

  21. Loading more headlines...

At a Glance

International Flavors & Fragrances, Inc.

521 West 57th Street

New York, New York 10019-2960

Phone

1 2127655500

Industry

Chemicals

Sector

Basic Materials/Resources

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$12.44B

Net Income

$-1.87B

2022 Sales Growth

6.7%

Employees

24,600

Annual Report for IFF

/news/pressrelease/company/us/iff

Press Releases on IFF

  1. IFF Reports First Quarter 2023 Results

    4:15 p.m. May 8, 2023

    - BusinessWire - BZX

  2. IFF Declares Dividend for Second Quarter 2023

    4:15 p.m. May 3, 2023

    - BusinessWire - BZX

  3. IFF to Release First Quarter 2023 Results May 8

    4:15 p.m. April 24, 2023

    - BusinessWire - BZX

  6. IFF Mourns the Passing of Board Chair Dale F. Morrison

    4:20 p.m. April 12, 2023

    - BusinessWire - BZX

  8. IFF Advances Softgel Technology for Complex Fill Formulations

    6:57 a.m. April 4, 2023

    - PR Newswire - PRF

  9. IFF Introduces New Animal Nutrition Solution for Piglets

    3:16 a.m. March 28, 2023

    - PR Newswire - PRF

  10. IFF Advances Softgel Technology for Complex Fill Formulations

    4:00 a.m. March 27, 2023

    - PR Newswire - PRF

  12. IFF Introduces New Animal Nutrition Solution for Piglets

    9:00 a.m. March 14, 2023

    - PR Newswire - PRF

Link to MarketWatch's Slice.